Pular para o conteúdo

Referência de medicamentos

Ciltacabtagene autoleucel

Ciltacabtagene autoleucel is a medicine in the class miscellaneous. It is used for multiple myeloma.

Última atualização Fontes: US FDA label

Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.

O conteúdo clínico desta página está disponível apenas em inglês.

Pontos-chave

Classe do medicamento
Miscellaneous
Código ATC
L01XL05
Interações conhecidas
68 (Grave: 46 · Moderada: 21 · Leve: 1)
Nomes comerciais
1
Países e mercados
1

Para que é usado

Como funciona

BCMA-directed, genetically modified autologous T cell immunotherapy. The CAR has two BCMA-targeting single-domain antibodies, a 4-1BB co-stimulatory domain and a CD3-zeta signaling domain. On binding BCMA-expressing cells, the CAR promotes T cell activation, expansion and elimination of target cells.

Dose habitual em adultos (resumo da bula)

Relapsed or refractory multiple myeloma: single IV infusion of 0.5–1.0×10^6 CAR-positive viable T cells per kg body weight; maximum 1×10^8 CAR-positive viable T cells per single infusion

Resumo da bula apenas da primeira linha de posologia; as seções completas de dose estão no aplicativo.

Gravidez e amamentação

Gravidez
Unsafe No data in pregnancy. CAR-T cells may cross the placenta and cause fetal B-cell depletion and low antibody levels. Not recommended in pregnancy or without contraception; confirm a negative pregnancy test before treatment.
Amamentação
Unknown No information on presence in milk or effects on the infant. Weigh breastfeeding benefits against the mother's need; follow the guidance for the lymphodepleting chemotherapy.

Efeitos adversos relatados

  • Pyrexia
  • Cytokine release syndrome
  • Hypogammaglobulinemia
  • Hypotension
  • Musculoskeletal pain
  • Fatigue

Advertências de caixa preta

  • Fatal or life-threatening CRS occurred; do not give to patients with active infection or inflammatory disorders; treat severe CRS with tocilizumab or tocilizumab and corticosteroids. Fatal or life-threatening ICANS, parkinsonism and Guillain-Barré syndrome occurred; monitor for neurologic events. HLH/MAS, prolonged and recurrent cytopenias, immune effector cell-associated enterocolitis, and secondary hematological malignancies (MDS, AML, T-cell malignancies) have occurred.

Quem deve ter cuidado

  • Increased early mortality in CARTITUDE-4: 14% of deaths in the CARVYKTI arm versus 12% in the control arm within 10 months
  • Monitor at least daily for 7 days for CRS and neurologic toxicities; confirm that a minimum of two doses of tocilizumab are available before infusion
  • Prolonged and recurrent cytopenias; monitor blood counts before and after infusion

Informe ao farmacêutico ou ao médico sobre gravidez ou amamentação, doença renal ou hepática, alergias e todos os outros medicamentos ou suplementos que você usa.

Principais interações (68)

All 68 interactions, with severity and what to do

Para assinantes do Pro+

Desbloqueie a página completa

Crie uma conta e comece um teste do Pro+ para abrir a monografia completa de Ciltacabtagene autoleucel: doses, gravidez e amamentação, efeitos adversos, advertências e todas as interações.

  • Dosing by age, kidney and liver function, and further dose lines
  • Renal and hepatic dose adjustments
  • Dosing in older adults
  • How to give it
  • Pharmacokinetics
  • Patient counselling points
  • IV preparation and dilution

Experimente o Pro+ grátis por 14 dias na web. Sem cartão.

Perguntas frequentes

What is Ciltacabtagene autoleucel used for?

Ciltacabtagene autoleucel is a medicine in the class miscellaneous. It is used for Multiple myeloma.

What side effects have been reported with Ciltacabtagene autoleucel?

Pyrexia, Cytokine release syndrome, Hypogammaglobulinemia, Hypotension, Musculoskeletal pain, Fatigue. Serious warning: Fatal or life-threatening CRS occurred; do not give to patients with active infection or inflammatory disorders; treat severe CRS with tocilizumab or tocilizumab and corticosteroids.

Can Ciltacabtagene autoleucel be taken in pregnancy or while breastfeeding?

Pregnancy: Unsafe. No data in pregnancy. CAR-T cells may cross the placenta and cause fetal B-cell depletion and low antibody levels. Not recommended in pregnancy or without contraception; confirm a negative pregnancy test before treatment. Breastfeeding: Unknown. No information on presence in milk or effects on the infant. Weigh breastfeeding benefits against the mother's need; follow the guidance for the lymphodepleting chemotherapy.

What does Ciltacabtagene autoleucel interact with?

MediHelp lists 68 known interactions for Ciltacabtagene autoleucel. Major: 46 · Moderate: 21 · Minor: 1. The most serious include Adalimumab, Anti-thymocyte, Azathioprine.

Monografias completas, posologia e verificador de interações no app MediHelp

Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.

Explorar de A a Z · Referência de medicamentos

Baixar o app Entrar